
On Saturday night, the controversy around the experimental cancer immunotherapy drug NKTR-214 ratcheted higher following a new data presentation at the American Society of Clinical Oncology annual meeting.
Nektar Therapeutics and Bristol-Myers Squibb, the owners of NKTR-214, are undertaking a hugely expensive program to run nearly two dozen clinical trials spanning 20 indications across nine types of solid tumors. Phase 3 studies in melanoma, kidney cancer, and urothelial cancer are starting soon.
I appreciate the clear way you laid out the issues involved.
I respectfully disagree. The data strongly suggests a 10-20% increase in activity over anti-PD1 monotherapy with little toxicity and ability to further combine and sequence with alternative checkpoint inhibitors and emerging TLR agonist drugs.
Thanks so much, a great article.
What is position on NKTR, are you short ?